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Abstract To show differences and similarities between
risk estimation models for breast cancer in healthy women
from BRCA1/2-negative or untested families. After a sys-
tematic literature search seven models were selected: Gail-
2, Claus Model, Claus Tables, BOADICEA, Jonker Model,
Claus-Extended Formula, and Tyrer–Cuzick. Life-time
risks (LTRs) for developing breast cancer were estimated
for two healthy counsellees, aged 40, with a variety in
family histories and personal risk factors. Comparisons
were made with guideline thresholds for individual
screening. Without a clinically significant family history
LTRs varied from 6.7% (Gail-2 Model) to 12.8% (Tyrer–
Cuzick Model). Adding more information on personal risk
factors increased the LTRs and yearly mammography will
be advised in most situations. Older models (i.e. Gail-2 and
Claus) are likely to underestimate the LTR for developing
breast cancer as their baseline risk for women is too low.
When models include personal risk factors, surveillance
thresholds have to be reformulated. For current clinical
practice, the Tyrer–Cuzick Model and the BOADICEA
Model seem good choices.
Keywords Breast cancer  Statistical models 
Risk assessment  Lifetime risk  Guidelines
Introduction
Breast cancer is the most common type of cancer in women
in western countries, and is an important cause of death for
women, especially in the age group 30–59 [1]. The most
important risk factor for the development of breast cancer,
besides advanced age, is a family history of breast cancer
[2]. In the past decades, many empirical and statistical
models have been developed to estimate the risk of
developing breast cancer during life, the life-time risk
(LTR). These models have been developed to guide clini-
cians to decide whether or not surveillance is indicated [3–
5]. Most of these models focus on family history of breast
cancer alone, but some use other risk factors additionally.
Although generally applicable to all women, the models
are mostly developed for healthy women who have rela-
tives with breast cancer and who are BRCA1/2 negative or
untested. For those healthy women who want more cer-
tainty about their breast cancer risk, the risk can only be
estimated by examining their pedigree. As the diversity of
models available is large, it is often difficult for clinicians
to decide which model to use for an individual counsellee.
The aim of this study is to show and evaluate the dif-
ferences and similarities between the different models in
risk estimates for breast cancer in healthy women. To be
able to provide a complete overview of risk assessment
models, a systematic literature search was performed to
find all available risk assessment models. Often used and
recently developed models of which risk assessment soft-
ware was available were selected and applied to cousellees
with varying personal risk factors and different pedigrees
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varying in affected relatives. The risk estimates of the
models were compared with the thresholds for individual
mammographic screening in guidelines.
The provided overview of observed strengths and
weaknesses of the models in these different individual
situations might help clinicians to make a founded choice
of a risk assessment model for their clinical practice.
Methods
Literature search for risk assessment models
The medical literature was searched systematically to find a
complete overview of existing breast cancer risk assessment
models, in PubMed (1950–September 2006), EMBASE
(1980–September 2006), and Web of Science (1945–
September 2006). The combination of two concepts, i.e.
familial breast cancer AND risk models, was extensively
searched either by the use of subject headings or free text
words (Appendix 1). The search revealed 522 unique
articles.
Three independent reviewers made a first selection
based on title and abstract, and a second selection based on
complete article readings. Excluded were: models dealing
with risk assessment using invasive or surveillance tech-
niques; models intended for non-healthy individuals;
models for psychological outcome; or models only focus-
ing on carrier status of genetic mutations. We selected 29
articles to be of interest. After studying the references to
check whether we may have missed relevant models, we
included an additional ten articles, leading to a total of 39
selected articles [6–44]. Among the total of 39 articles, 18
were related to 12 different breast cancer risk assessment
models or methods [6–23].
Risk assessment models and methods
From the identified models, we selected those models or
methods that are still in use: Gail2-Model, Claus Model
and Claus Tables [8–10, 15], and for which risk estimates
could be obtained by software availability or because a
formula or reading tables are included in the article: BO-
ADICEA Model, Jonker Model, Tyrer–Cuzick Model, and
Claus-Extended Formula [16–18, 21, 22] (Table 1). The
models of Gail and Tyrer–Cuzick [8, 21] incorporate, next
to family history and age, information on personal risk
factors. The selected models vary upon the life-time age for
which the risks are estimated. The Claus Model, Claus
Tables, Claus-Extended Formula, Jonker Model, Tyrer–
Cuzick Model, and BOADICEA Model use an end-age of
80 years, and the Gail-2 Model 90 years.
When using the available software, the Gail-2 and
Tyrer–Cuzick Model provide remaining life-time risks (i.e.
40–80 or 90 years), whereas the other models provide full
life-time risks (i.e. 0–80 years).
Counsellees and pedigrees
The counsellees are examples of women who might ask
to be informed about their LTR for breast cancer and
additional management strategies if needed. The first
concerns Counsellee A, 40 years of age, of Caucasian
origin, without a history of LCIS/DCIS. She reflects a
counsellee of whom family cancer data were included, but
no questions were asked about personal risk factors. The
second concerns Counsellee B, with identical character-
istics as Counsellee A, but additional information was
asked for; she has had one biopsy, is 170 cm (5.6 ft) in
height and 65 kg (143 lbs) in weight. Additionally she
provided information on two other personal risk factors,
i.e. age at first menstrual period and age at first born
child. These two factors are varied to study the impact on
risk estimates.
In addition, these two counsellee’s have identical family
history for breast and ovarian cancer, which we varied in
six different pedigrees (Fig. 1). Each of these pedigrees
consisted of a counsellee (Counsellee A without informa-
tion on personal risk factors or Counsellee B with
information on personal risk factors), with a brother and a
sister aged 46 and 45, respectively. The mother died
60 years old and the father is alive and 74 years old. In
case of a maternal or paternal aunt, this aunt died at age 55.
In case of presented grandparents, whether they are from
the maternal or paternal side, the grandmother died at age
55 and the grandfather at age 74.
Breast cancer risk estimation and analysis
We calculated the breast cancer risk for Counsellee A,
using her age and family history, and for Counsellee B,
including age, family history, medical history and personal
risk factors. Risks for Counsellee B were only estimated
using the Gail-2 and the Tyrer–Cuzick Model, as these are
the only models including personal risk factors into the
estimation. Her risks are identical with the risks of Coun-
sellee A according to the other models. By calculating the
risks for Counsellee A using the Gail-2 and the Tyrer–
Cuzick Model, the personal risk factors included in these
models were set to unknown or not available. By reading
the Claus Tables, we included as many affected family
members as possible. The Claus Tables seem to use strict
combinations of affected family members, such as an
affected mother and maternal aunt in Table 5. However,
we used these tables more freely by reading them as
affected first degree relatives combined with second-degree
maternal or paternal relatives (Personal communication by
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e-mail with dr. Elizabeth Claus at date Sept. 24, 2005). So,
for pedigree 1 we used Claus Table number 3, for pedigree
2 table number 5, for pedigree 3 table number 4 (with
exclusion of the grandmother), for pedigree 4 table number
5 (with exclusion of the grandmother), for pedigree 5 table
number 6 (with exclusion of the grandmother), and for
pedigree 6 table number 2 (without a possibility of
including the ovarian cancer of the mother).
The outcomes of the models were compared with the
threshold in national guidelines for individual mammo-
graphic screening. In the UK, a LTR of 17% or higher is an
indication for an increased LTR, i.e. ‘moderate risk’,
whereas in the Netherlands this threshold is 20%. Both
guidelines classify women with risks of 30 and over as the
‘high risk’ group (www.nice.org.uk/CG041; www.cbo.
nl/product/richtlijnen/folder20021023121843/mammac_rl_
2005.pdf/view). In this analysis, both guidelines were
applied.
Recommended surveillance for those in the moderate
risk group is a mammography annually aged 40–49 years.
From age 50 years, population screening is offered. For
those with a high risk, surveillance is usually offered at age
35 years (NL) or 40 years (UK) and continues up to
50 years (UK) or up to 60 years (NL), after which popu-
lation screening is offered.
Results
Estimated LTRs developing breast cancer
for Counsellee A
Counsellee A in pedigree 1 represents a woman without a
significant family history for breast cancer. Her risk
according to all models was below the threshold for
moderate risk, i.e. 17%, with 6.7% (Gail-2 Model) as the
lowest and 12.8% (Tyrer–Cuzick Model) as the highest
estimate (Table 2). In pedigree 2 with an affected sister and
maternal aunt the risk estimates were more divided with
16.4% as the lowest (Gail-2 Model) and 28.9% as the
highest estimate (Claus Tables). A difference of 20%
between the lowest and highest estimate was observed in
pedigree 3 (breast cancer in three generations). The BO-
ADICEA model estimated the lowest risk (22.6%) and the
Claus Tables the highest risk (43.0%), all at least a mod-
erate risk. In pedigree 4 with one-first- and two-second-
degree affected relatives in the maternal family, the lowest
risk estimate for Counsellee A was 16.4% (Gail-2 Model)
and the highest was 33.2% (Claus Model). In pedigree 5, a
similar situation but in the paternal family, the lowest risk
estimate was 14.4% (Claus Tables) and the highest 39.4%
(Claus Model). In pedigree 6 there was also an ovarian
Fig. 1 Drawings of the six
pedigrees, for which breast
cancer risks were assessed.
(a square represents male; a
circle represents a female; a full
black circle represents a female
with breast cancer (BC), circles
with a black horizontal line
represent a female with ovarian
cancer (OC); the number below
the circles and square represent
the current age or age at death
of that person; if that person had
breast or ovarian cancer, the age
at diagnosis follows the type of
cancer on the line below, e.g.
BC45 means breast cancer at
age 45)
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cancer diagnosed, leading to a lowest risk estimate of
12.1% (Claus Model) and a highest of 25.2% (Jonker
Model).
Estimated LTRs developing breast cancer for
Counsellee B
Adding information on the age at first menstrual period and
the age at first born child always resulted in an increase of
the estimated LTR for developing breast cancer of Coun-
sellee B, except when the counsellee had her first child at
the age of 19 (Table 3). In this situation, the Tyrer–Cuzick
model estimates her risk as lower than the risk for Coun-
sellee A, for whom no information on the personal risk
factors was available.
Without a significant family history of breast cancer, as
in pedigree 1, the estimates of the Tyrer–Cuzick Model are
always higher than those of the Gail2 Model, but these
differences are clinically not significant. For Counsellee B
in pedigree 3, with breast cancer in three generations, the
estimates of the Gail-2 Model are for all, but one, variants
of the personal risk factors higher, varying from 29.6% to
49.1%, than those of the Tyrer–Cuzick Model (20.2–
33.7%). For Counsellee B in pedigrees 2, 4, 5 and 6, the
estimates are rather comparable.
Related management strategies
Using the thresholds for individual mammographic
screening of guidelines (C17% LTR in UK and C20%
LTR in the Netherlands), different decisions regarding the
optimal management strategy were found when different
models were used. Without a significant family history
(pedigree 1), the models all agreed that there is no indi-
cation to offer her mammographic screening before the age
of 50. All models agreed that Counsellee A in pedigree 3
had at least a moderate LTR for developing breast cancer
(C17%). The models differed in their advice for Counsel-
lee A in pedigrees 2, 4, 5 and 6, where the newer models
(BOADICEA, Jonker Model, Claus-Extended Formula and
Tyrer–Cuzick Model) had a high level of agreement. For
Counsellee A in pedigree 2, two models, i.e. Gail-2 Model
and BOADICEA Model, advised not to start early
screening according to the UK guideline, while three
models, i.e. Claus Model, Jonker Model, and Claus-
Extended Formula, reached an estimate between the UK
and Dutch threshold of moderate risk. The newer models
agreed that Counsellee A in pedigree 3, 4, 5 and 6 had a
moderate risk, while the older models also reached risks
below the moderate threshold.
Using the guidelines with risk thresholds based on family
history alone, for Counsellee B, the management strategies
are somewhat different. In pedigree 1, without a significant
family history of breast cancer, the Gail-2 Model and the
Tyrer–Cuzick Model reached a moderate risk when the
menstrual period had started at the age 11 and when her first
child was born at age 30 or when she had had no children at
all. The two models also agreed for most situations that
Counsellee B had an indication for yearly mammography in
nearly all other pedigrees, irrespective of the age of the first
menstrual period or the age at first born child.
Discussion
In this study we report on breast cancer LTR estimates
using several risk assessment models for two healthy
counsellees with different risk factors included in six dif-
ferent pedigrees. When we compared the risk estimates of
the different models with the thresholds for individual
mammographic screening (C17% LTR in UK and C20%
LTR in the Netherlands), different decisions regarding
optimal management strategies were found.
Table 2 Risk assessment for
Counsellee A, applying the
seven models
pedigree Gail-2 Model Claus Model Claus Tables BOADICEA
Model























16.4% 39.4% 14.4% 20.2% 27.3% 20.8% 23.1%
6 Mother OC55
Sister BC45 16.4% 12.1% 13.2% 18.8% 25.2% 20.3% 19.8%
30% gray Moderate risk 
50% gray High risk 
Breast Cancer Res Treat (2009) 115:381–390 385
123
Counsellee A in pedigree 1 represents a woman without
a clinically significant family history of breast cancer. Her
risk varied from 6.7% to 12.8%. The older models and
methods, providing 6.7% (Gail-2 Model), 8.4% (Claus
Model) and 9.4% (Claus Tables), were developed in the
eighties and nineties, when the incidence of breast cancer
was significantly lower than now-a-days. The four newer
models have baseline risks more likely representing the
current incidence of breast cancer in the USA and Western-
European countries [45], with baseline risks varying from
10.1% to 12.8% at age 40. It is important for breast cancer
risk assessment models that their estimated risks for a
population represent the current overall population inci-
dence. As the breast cancer incidence has risen over the
years, it is likely that the older models underestimate the
overall breast cancer incidence.
Counsellee A in pedigree 6 represents a woman with a
family history of breast and ovarian cancer. Only the four
newer models have incorporated ovarian cancer. It is
therefore according to the expectation that these models,
i.e. BOADICEA Model, Jonker Model, Claus-Extended
Formula and Tyrer–Cuzick Model, yield higher estimates
for this situation compared to the models that ignore
ovarian cancer in relatives, i.e. Gail-2 Model, Claus Model
and Claus Tables.
We have shown that information on the age of the first
menstrual period and the age at first born child increases
the estimated LTRs for developing breast cancer, except
for the situation in which the counsellee had her first child
at the age of 19 (Tyrer–Cuzick Model estimate). It can be
expected that adding more information on risk factors to
the counsellee will further increase these risk estimates,
Table 3 Risk assessment for
Counsellee B, given six
different pedigrees and two
different risk factors, applying
the Gail-2 Model and the Tyrer–
Cuzick Model
On the first row the risks for
Counselee A, with unknown
personal risk factors, is given as
a reference
386 Breast Cancer Res Treat (2009) 115:381–390
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and yearly mammography will then be advised more often
if models including this information are used. One has to
remember, however, that in this current situation the risk
estimate of the counsellee reached a level above the 17%
through adding personal factors into the model, while the
screening thresholds from current guidelines are based on
family history risks only (www.nice.org.uk/CG041).
Remarkable in this respect are the risk estimates outcomes
in our study for a counsellee without a significant family
history and a first menstrual period at the age of 11 and the
age at her first born child of 30 or when she had had no
children at all. The Gail-2 Model and the Tyrer–Cuzick
Model agreed in these situations and gave a LTR between
17.9 and 18.4% for which a yearly mammography is
offered in the UK based on the threshold for moderate risk.
Interesting to note is that in the example of pedigree 5,
which includes a sister, a paternal aunt and the paternal
grandmother with breast cancer, large differences in risk
estimates between the Claus Tables, i.e. 14.4%, and the
Claus Model, i.e. 39.4%, were found. Although the Claus
Tables were developed as summary tables of the Claus
Model, the Tables apparently do not represent the Claus
Model estimates in a very precise manner. The Claus Model
is able to include all three family members into the risk
estimate. The Claus Tables can only include two family
members of this three generation breast cancer family.
For women at increased risk to develop breast cancer,
surveillance and preventive measures may be provided as
an attempt to decrease mortality. In this study we have
evaluated the results in breast cancer risk estimates of
seven different models or methods. All models base their
risk estimates on the family history for breast cancer. In
four models, the presence of ovarian cancer could be used,
and two of the seven models also incorporate personal risk
factors. The only situations in which similar advice to start
screening was reached were for Counsellee A in pedigree 1
regarding no-screening and in pedigree 3 (a sister with
breast cancer at 45 and a maternal aunt with breast cancer
at 55 years) for screening. In the latter situation, all models
reached at least a moderate risk, but three models (Gail
Model, Claus Model and Claus Tables) even reached a high
risk estimate for this counsellee. For clinical counsellors,
however, women at the lowest and highest ranges of risk
are usually not the problem for decisions regarding sur-
veillance. Pedigrees that reach breast cancer risks in the
group extremes, such as between 29% and 31% or around
17% or 20%, are the ones that make decision making hard.
The models that we have tested in this study do not provide
consensus in these matters. Another problem that we have
encountered was that some of the models actually provide
remaining life-time risks, thus from age 40 up to age 80 or
90 instead of full life-time risks (e.g. Tyrer–Cuzick and
Gail Model). In the final risk overviews that these models
provide, they use the term life-time risk and not remaining
life-time risk. One may be confused by this. A problem
with the remaining life-time risk strategy is that current
guidelines have been formulated upon full life-time risks.
Although an estimate of remaining life-time risk is more
accurate for the individual woman, it feels unjust to relate
this risk to current guideline thresholds. In the overview
here provided the full life-time risks and remaining life-
time risks do not differ that much, as the breast cancer risk
for any woman is relatively low up to age 40; varying from
0.4% to 4.1%, depending on the different models and the
varying pedigrees presented here (data not shown).
For women with the other pedigrees (Counsellee A with
pedigree 2, 4, 5 or 6), the use of risk assessment models
seems useful, as the decision regarding screening or no-
screening is not self-evident. In these cases, objective
decision support would make it possible to standardize
clinical behaviour. The varying outcomes of the different
models for an identical pedigree present the current prob-
lem for clinical practice. Clinical counsellors often depend
on their years of experience by judging a pedigree. This
experience, however, cannot be transferred to young,
inexperienced, health care professionals. Evidence-based
clinical behaviour is therefore of utmost importance,
because it is reproducible and not coloured by clinical
experience. Although each of the existing models shows
limitations, the documented use of such a model will make
the risk estimation process more uniform and reproducible.
When a decision should be made for the use of risk
assessment models in clinical practice, several factors play
a role. First, a model should be easy to use. Although, the
Claus Tables are easy to use in clinical practice, these tables
ignore much information from the pedigree, e.g. presence of
bilateral breast cancer and ovarian cancer, so these Tables
should not be recommended for use. Also Amir et al. [33]
concluded that the Claus Model, among others, significantly
underestimate breast cancer risk. The Claus-Extended
Formula was developed to overcome these problems.
A second point is that the model should be validated. In
validating a risk assessment model, the most important
characteristics of risk model performance are calibration,
discrimination, and accuracy [46]. Validation studies
regarding these models have shown that the Tyrer–Cuzick
Model as well as the BOADICEA perform well [33, 47,
48], although improvements are always possible.
A third point concerns the question which factors
should be included in the preferred model. As it is widely
acknowledged that personal risk factors may play a role
in a person’s breast cancer risk, it may be recommendable
to use a model that includes these personal risk factors
into the risk assessment. Familial factors have been
acknowledged to be one of the most important for breast
cancer with relative risks up to 6–8, but personal risk
Breast Cancer Res Treat (2009) 115:381–390 387
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factors such as atypical hyperplasia have been shown to
also increase breast cancer risk considerable with a rela-
tive risk of 3–4 [2]. In addition, it can be argued that
information regarding genetic modifiers such as CHEK2-
1100delC and a number of SNP’s should be also included
in an optimal model [49, 50]. On the other hand, thus far,
the LTRs related to these genetic modifiers and the
interaction between these and personal risk factors are
unknown, as is the interaction between the different per-
sonal risk factors. It is unlikely that the personal risk
factors each have an independent impact on breast cancer
risk. This problem makes it hard to include these factors
into a risk assessment model that contains more than one
breast cancer risk factor. However, the Tyrer–Cuzick
Model proves to be a good example of a multiple factor
model, as the validation study by Amir et al. showed [33].
They concluded that the Tyrer–Cuzick Model is the most
consistently accurate model for prediction of breast can-
cer, among the models they tested.
Finally, a model should be up-to-date. The incidence of
breast cancer is increasing, for that the LTRs for devel-
oping breast cancer are increasing. The occurrence of risk
factors is also increasing. There is a trend that more women
will have their first born child after the age of 30 and the
age of the first menstrual period is decreasing. For that
reasons, a model should be fit on the target population.
Another option is to start yearly mammography for women
aged 40–50 [51, 52]; the question for which women
screening for breast cancer is indicated outside the popu-
lation screening for breast cancer will become obsolete.
One has to keep in mind that the management strategies
proposed in current guidelines have been formulated based
on cancer family history alone, and are not based on the
combination of family history and personal risk factors of
the counsellee.
Our results show that it is recommendable to use one of
the newer models. Older models underestimate the baseline
life-time risk for breast cancer. Using a model including
personal risk factors will increase insight in the variation in
risk estimates. Therefore we conclude that the Tyrer–
Cuzick Model and the BOADICEA Model seem a good
choice for current clinical practice.
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Appendix 1: Literature search
In all search engines, the two concepts ‘‘Familial breast
cancer’’ and ‘‘Risk models’’ are represented by different
variations or permutations of relevant terms.
PubMed (1950–2006)
In PubMed, words or phrases without field descriptions are
mapped automatically to the appropriate field descriptions
such as title, abstract, MeSH (Medical Subject Headings),
MaJR (Major Medical Subject Headings). The concepts are
combined, using the following search strategy:
(‘‘familial breast cancer risk’’ OR (‘‘breast cancer fam-
ilies’’ AND risk) OR (‘‘breast cancer family’’ AND risk)
OR (‘‘risk assessment’’ AND ‘‘familial breast cancer’’))
AND ((risk[ti] AND (model[ti] OR assessment[ti]) OR
((‘‘Models, Statistical’’[Majr] OR ‘‘Models, Genetic’’
[Majr]) AND ‘‘Probability’’[Mesh]))) OR (‘‘Breast Neo-
plasms/genetics’’[Majr] OR (breast cancer AND (‘‘Mass
Screening’’[MeSH] OR ‘‘Genetic Services’’[MeSH] OR
familial OR family OR families OR gene OR genes OR
‘‘Genetic Predisposition to Disease’’[MeSH]))) AND
((risk[ti] AND (model[ti] OR assessment[ti]) OR ((‘‘Mod-
els, Statistical’’[Majr] OR ‘‘Models, Genetic’’[Majr]) AND
‘‘Probability’’[Mesh])))
EMBASE (1980–2006)
In EMBASE, subject headings and free text words are used
in combination. Subject headings are marked with ‘/’ at the
end of the specific term and are ‘‘exploded’’, i.e. the nar-
rower subject headings are also selected automatically. The
following field descriptions were used for free text terms:
mp = title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer, drug man-
ufacturer name; ti = title. The concepts are combined,
using the following search strategy:
(familial breast cancer risk.mp OR (breast cancer fam-
ilies AND risk).mp OR (breast cancer family AND
risk).mp OR (risk assessment AND familial breast can-
cer).mp) AND ((risk.ti AND (model.ti OR assessment.ti)
OR ((exp mathematical model/) AND exp risk/))) OR ((exp
*Breast Cancer/AND genetic$.mp) OR (exp Breast Can-
cer/AND (exp genetic service/OR exp cancer screening/OR
familial.mp OR family.mp OR families.mp OR gene.mp
OR genes.mp OR exp multifactorial inheritance/))) AND
((risk.ti AND (model.ti OR assessment.ti) OR ((exp
mathematical model/) AND exp risk/)))
Web of Science (1945–2006)
In the Web of Science, free text words are used in com-
bination. Words preceded by TI are searched in the field
title. Words preceded by TS are searched in the fields
abstract, keywords, or title. The concepts are combined,
using the following search strategy:
(((TS=‘‘risk assessment’’ AND TS=‘‘familial breast
cancer’’) OR TS=‘‘familial breast cancer risk’’ OR
388 Breast Cancer Res Treat (2009) 115:381–390
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(TS=‘‘breast cancer families’’ AND TS=risk) OR
(TS=‘‘breast cancer family’’ AND TS=risk)) AND ((TI=risk
AND (TI=model OR TI=assessment)) OR (TS=model*
AND TS=risk*))) OR (((TI=‘‘Breast Cancer’’ OR
TI=‘‘breast tumor*’’ OR TI=‘‘breast tumour*’’ OR
TI=‘‘breast carcin*’’ OR TI=‘‘breast neoplas*’’) AND
(TS=‘‘genetic screen*’’ OR TS=‘‘cancer screen*’’ OR
TS=famil* OR TS=gene OR TS=genes OR TS=predispos*
OR TS=susceptib*)) AND ((TI=risk* AND (TI=model* OR
TI=assessment)) OR (TS=model* AND TI=risk*))) OR
((((TI=‘‘Breast Cancer’’ OR TI=‘‘breast tumor*’’
OR TI=‘‘breast tumour*’’ OR TI=‘‘breast carcin*’’ OR
TI=‘‘breast neoplas*’’) AND TI=genetic*)) AND ((TI=risk*
AND (TI=model* OR TI=assessment)) OR (TS=model*
AND TI=risk*)))
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